Decoding real-world outcomes: exploring clinical features associated with efficacy in patients treated with dupilumab. Mendeley Supplements.

1. Supplemental Materials including: Supplemental Table 1: Patients’ demographics and baseline disease characteristics. Supplemental Table 2: Patient-reported outcomes with treatment of dupilumab in 16 weeks among different age groups. Supplemental Table 3: Associations between patients’ characteristics and EASI-75 at week 16 among different age groups. Supplemental Table 4: Adverse events while on dupilumab therapy among different groups. Supplementary Figure 1: Graphical abstract. Supplementary Figure 2: Predictability of week 16 EASI-75 responses by PP-NRS change from baseline at week 2 with dupilumab. 2.Supplemental Methods